Inventor · disambiguated record
Joan Mannick
Also filed as: MANNICK JOAN
21 granted patents·14 pending applications·235 citations·filing 2002–2025
94Inventor score
Top patents by PatentIndex Score
35 records- 0197US10174095B2Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Jan 8, 2019·41 cites·50 claims
- 0297US9815901B2Treatment of cancer using a CD123 chimeric antigen receptorBROGDON JENNIFER·Filed 2015·Granted Nov 14, 2017·94 cites·40 claims
- 0396US10004803B2Low, immune enhancing, dose mtor inhibitors and uses thereofNOVARTIS AG·Filed 2016·Granted Jun 26, 2018·13 cites·11 claims
- 0495US11084880B2Anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Aug 10, 2021·15 cites·24 claims
- 0595US10357514B2Treatment of cancer using anti-CD19 Chimeric Antigen ReceptorUNIV PENNSYLVANIA·Filed 2015·Granted Jul 23, 2019·18 cites·45 claims
- 0695US10286069B2Low, immune enhancing, dose MTOR inhibitors and uses thereofNOVARTIS AG·Filed 2018·Granted May 14, 2019·8 cites·11 claims
- 0794US10287354B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted May 14, 2019·29 cites·63 claims
- 0891US10774388B2Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereofNOVARTIS AG·Filed 2015·Granted Sep 15, 2020·7 cites·31 claims
- 0985US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 1083US11578130B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·1 cites·30 claims
- 1183US10703819B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Jul 7, 2020·1 cites·33 claims
- 1279US2023220090A1Treatment of cancer using a cd123 chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1377US10441584B2Methods of enhancing immune responseNOVARTIS AG·Filed 2017·Granted Oct 15, 2019·2 cites·23 claims
- 1472US2020054742A1Low, immune enhancing, dose mtor inhibitors and uses thereofNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1572US2015140036A1Low, immune enhancing, dose mtor inhibitors and uses thereofMANNICK JOAN·Filed 2014·Application pending·0 cites
- 1672US2023026049A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1770US12214037B2Treatment of cancer using humanized anti-BCMA chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Feb 4, 2025·0 cites·16 claims
- 1870US11591404B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 1970US2023052970A1Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2065US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2164US12252518B2Methods of treating non-arteritic anterior ischemic optic neuropathyLIFE BIOSCIENCES INC·Filed 2023·Granted Mar 18, 2025·0 cites·30 claims
- 2264US2020339651A1Methods for b cell preconditioning in car therapyNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2362US11045463B2Methods of enhancing immune responseNOVARTIS AG·Filed 2019·Granted Jun 29, 2021·0 cites·24 claims
- 2462US10993940B2Methods of enhancing immune responseNOVARTIS AG·Filed 2019·Granted May 4, 2021·0 cites·24 claims
- 2562US2019388471A1Treatment of cancer using anti-cd19 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2662US2021172020A1Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2755US2025263455A1Methods of treating non-arteritic anterior ischemic optic neuropathyLIFE BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 2854US11459390B2Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Oct 4, 2022·0 cites·21 claims
- 2954US2021030741A1Pharmaceutical combination of everolimus with dactolisibNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3054US2017274014A1Combinations of low, immune enhancing, doses of mtor inhibitors and carsBROGDON JENNIFER·Filed 2014·Application pending·0 cites
- 3151US10576076B2Pharmaceutical combination of everolimus with dactolisibGLASS DAVID·Filed 2016·Granted Mar 3, 2020·0 cites·21 claims
- 3251US2018334490A1Methods for b cell preconditioning in car therapyBROGDON JENNIFER·Filed 2015·Application pending·0 cites
- 3344US7419834B2System for detection of nitrosylated proteinsUNIV MASSACHUSETTS·Filed 2002·Granted Sep 2, 2008·0 cites·26 claims
- 3442US2008199967A1System for Detection of S-NitrosoproteinsUNIV MASSACHUSETTS MEDICAL·Filed 2008·Application pending·0 cites
- 3534US10596165B2Combination therapiesRESTORBIO INC·Filed 2019·Granted Mar 24, 2020·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Joan Mannick files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →